title: Gd-EOB-DTPA-enhanced magnetic resonance imaging findings of nondiffuse fatty change of the liver.
abstract: OBJECTIVE
  To evaluate the difference in enhancement effects between the area of fatty change and the area of nonfatty change in patients with nondiffuse fatty change of the liver at gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance (MR) imaging.
  
  
  METHODS
  Thirteen patients with nondiffuse fatty change of the liver underwent Gd-EOB-DTPA-enhanced MR imaging including dynamic study using a 1.5-T MR unit. Dynamic contrast-enhanced (DCE) MR images were obtained at pre, arterial phase (25 seconds), portal phase (70 seconds), equilibrium phase (3 minutes), and hepatobiliary phase (10, 15, 20 minutes). The percentage differences of signal enhancement ratio were calculated from signal intensity measurement of the liver in each phase of DCE study and were compared between the area of fatty change and the area of nonfatty change in all phases.
  
  
  RESULTS
  In the all phases on DCE study, there were no significant differences in the signal enhancement ratio between the area of fatty change (27.7% ± 14.8%, 58.2% ± 14.7%, 62.7% ± 10.6%, 80.4% ± 15.2%, 84.9% ± 16.2%, 88.0% ± 14.3%) and the area of nonfatty change (29.9% ± 16.6%, 54.9% ± 13.3%, 63.0% ± 8.8%, 75.7% ± 12.6%, 80.3% ± 15.7%, 86.4% ± 14.5%) (P = 0.613).
  
  
  CONCLUSIONS
  Although our results are limited by the small number of patients, our results showed that the presence of fatty change of the liver did not affect the hepatic contrast enhancement effects of Gd-EOB-DTPA in all phases on dynamic study. This indicates that Gd-EOB-DTPA may be a reliable marker to identify areas of nondiffuse fatty change of the liver.
authors.affiliation: Department of Radiology, Kawasaki Medical School, Kurashiki, Okayama, Japan. jiro@med.kawasaki-m.ac.jp
authors.forename: Akira
authors.initials: A
authors.lastname: Yamamoto
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Tamada
authors.forename: Teruki
authors.initials: T
authors.lastname: Sone
authors.forename: Hiroki
authors.initials: H
authors.lastname: Higashi
authors.forename: Takenori
authors.initials: T
authors.lastname: Yamashita
authors.forename: Katsuyoshi
authors.initials: K
authors.lastname: Ito
mesh_terms: D000328:Adult; D003287:Contrast Media / Q000008:administration & dosage*; D005234:Fatty Liver / Q000473:pathology*; D005260:Female; D019786:Gadolinium DTPA / Q000008:administration & dosage*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged
chemical_list: D003287:Contrast Media; C073590:gadolinium ethoxybenzyl DTPA; D019786:Gadolinium DTPA